title: Controlled release of modified insulin glargine from novel biodegradable injectable gels.
abstract: The objective of this study was to investigate the duration of biological effects of modified insulin glargine released from a novel biodegradable injectable gel in type II diabetic Zucker diabetic fatty (ZDF) rats. Modified insulin glargine was purified from the marketed formulation by process of dialysis followed by freeze-drying, and the purity was confirmed by the single peak, corresponding to insulin glargine in the HPLC chromatogram. To determine and to compare the biological activity of purified insulin glargine with marketed formulation, it was suspended in isotonic saline solutions and administered subcutaneously to ZDF rats at a dose of 10 IU/kg of insulin and the blood glucose levels were measured. The blood glucose levels of ZDF rats after a subcutaneous injection of a suspension of purified insulin glargine decreased below 200 mg/dL within 2 h and remained at this level up to 6 h, then steadily raised above 400 mg/dL in 12 h. Insulin glargine particles were loaded into a novel biodegradable injectable gel formulation prepared from a blend of polylactic-co-glycolic acid (PLGA) and biocompatible plasticizers. Approximately 0.1 mL of insulin glargine-loaded gel prepared with PLGA was administered subcutaneously to the ZDF rats, and blood glucose levels were measured. The PLGA gel formulations prepared with insulin glargine particles had duration of action of 10 days following a single subcutaneous injection. The addition of zinc sulfate to the formulations prepared with purified insulin glargine particles further slowed down the drop in blood glucose concentrations.
authors.affiliation: Department of Pharmaceutical Sciences, University of Tennessee, Memphis, USA. omganand@gmail.com
authors.forename: Om
authors.initials: O
authors.lastname: Anand
authors.forename: Hassan
authors.initials: H
authors.lastname: Almoazen
authors.forename: Nitin
authors.initials: N
authors.lastname: Mehrotra
authors.forename: James
authors.initials: J
authors.lastname: Johnson
authors.forename: Atul
authors.initials: A
authors.lastname: Shukla
mesh_terms: D000818:Animals; D001682:Biological Availability; D003692:Delayed-Action Preparations; D005782:Gels; D006801:Humans; D007267:Injections; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage* / Q000378:metabolism*; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting / Q000008:administration & dosage* / Q000378:metabolism*; D008297:Male; D051381:Rats; D011924:Rats, Zucker
chemical_list: D003692:Delayed-Action Preparations; D005782:Gels; D007328:Insulin; D049528:Insulin, Long-Acting; D000069036:Insulin Glargine